Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 13/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409305 | 0.89 | TTK (0.55) | TTKADORA3 | |
| SCHEMBL12409243 | 0.88 | TTK (0.57) | TTKADORA3 | |
| SCHEMBL12409289 | 0.87 | TTK (0.56) | TTKADORA3PIM1 | |
| SCHEMBL12409259 | 0.86 | TTK (0.55) | TTKMAPTADORA3 | |
| SCHEMBL12409282 | 0.86 | TTK (0.55) | TTKTP53GAAMAPTPOLB | |
| SCHEMBL12409244 | 0.85 | TTK (0.68) | TTKTP53GAAADORA3 | |
| SCHEMBL14668729 | 0.83 | TTK (0.53) | TTKTP53GAAMAPTADORA3 | |
| SCHEMBL12409255 | 0.83 | TTK (0.52) | TTKGAAMAPTADORA3 | |
| SCHEMBL12409268 | 0.83 | TTK (0.52) | TTKGAAPOLBADORA3 | |
| SCHEMBL12409272 | 0.83 | TTK (0.65) | TTKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193131-B1 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LTD (GB) | 2013-01-30 | — | — | EP | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | TTK 3239/4885TP53 3068/4885GAA 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.